EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

A new study published in the British Journal of Urology International found that sarcopenia was linked to increased the risk ...

The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment ...

Bladder cancer treatment continues to evolve with a growing emphasis on balancing oncological efficacy and quality of life. Traditional approaches such as radical cystectomy, which involves ...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging ...

In June 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive intismeran autogene and pembrolizumab are alive and cancer free longer than those who receive placebo and ...

Unlike conventional bladder cancer, which has a consistent look under the microscope and succumbs predictably to therapy, the deadliest bladder tumors, collectively known as histologic variant (HV ...

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. bladder cancer patients has crossed the FDA finish line as UroGen Pharma ...